阿达木单抗治疗成年活动性强直性脊柱炎患者对其生存质量的影响

Effect of adalimumab on quality of life in patients with active ankylosing spondylitis

目的探讨阿达木单抗治疗成年活动性强直性脊柱炎(AS)患者在改善生存质量方面的效果。方法本研究为阿达木单抗与安慰剂随机双盲对照临床试验的事后分析,在临床研究中,AS患者按照2∶1的比例随机分配至阿达木单抗组或安慰剂组治疗12周,其中阿达木单抗组予阿达木单抗治疗,每次40 mg,每2周1次。在用药前和用药第12周发放健康调查简表(SF-36),让患者对其健康状况自行评分。结果接受阿达木单抗治疗的AS患者,在生理机能、躯体疼痛和社会功能方面的改善均优于安慰剂组(P均<0.05)。阿达木单抗组在生理机能、生理职能、躯体疼痛、总体健康、精力和社会功能评分中均较基线期有所提高(P均<0.05)。结论阿达木单抗可有效提高成年活动性AS患者的生存质量。

Objective To evaluate the efficacy of adalimumab in improving the quality of life of adult patients with active ankylosing spondylitis(AS).Methods This was a post-hoc study of the randomized,double-blind controlled clinical trial of adalimumab and placebo in AS patients.In this clinical trial,AS patients were randomly divided into the 12-week adalimumab and placebo groups according to the proportion of 2∶1.In the adalimumab group,AS patients were treated with adalimumab at a single dose of 40 mg,once every two weeks.The SF-36 Quality of Life Questionnaire was distributed to patients to self-evaluate health status before and at the 12th week after medication,respectively.Results AS patients in the adalimumab group obtained significant improvement in the scores of physiological functioning,bodily pain and social functioning compared with their counterparts in the placebo group(all P<0.05).In the adalimumab group,the scores of physical functioning,role-playing physical functioning,bodily pain,overall health,vitality and social functioning after 12-week medication therapy were improved compared with the baseline scores(all P<0.05).Conclusion Adalimumab is beneficial to enhancing the quality of life of adult patients with active AS.